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Abstract
High Dose Methotrexate (HD-MTX) toxicity can cause renal dysfunction in patients due to a presence of risk
factors such as body mass index >25 kg/m2, comedication (salicylates, NSAID`s, sulfonamides, beta-lactam
antibiotics, aminoglycosides), urine pH<7, iv fluid intake <3 l/m2/24 hours, hepatic dysfunction, renal insufficiency
prior to HD-MTX, diarrhea and pleural effusions. To prevent renal dysfunction and further MTX toxicity Glucarpidase
can be used which degrades MTX to its metabolites.
Cases: A 17 year-old and a 14 year-old boy were treated with HD-MTX, developed renal insufficiency and were
treated with Glucarpidase. In both patients unexpected renal dysfunction was seen still 3-4 weeks after treatment
with Glucarpidase. A theoretic concern regarding the use of Glucarpidase is that the rapid formation of MTX
metabolite called DAMPA, which is almost 10-fold less soluble than MTX, may lead to further renal toxicity by
precipitation in the renal tubules. If we compare our patient data with data we found in the literature there is almost
no difference in renal dysfunction duration between patients who got Glucarpidase (21 days) and those with only
supportive therapy (19 and 12 days). After treatment with Glucarpidase the question on how and when to restart HD-
MTX therapy raised. The safe option for our two patients would be first a rechallange with 50-75% HD-MTX after a
full recovery of the renal function. After the first rechallange kindey function and MTX levels should be closely
monitored and if no problems are observed the second rechallange should be with 100% HD-MTX. If we closely look
at our data and available data from the published articles there is a concern on how effective and safe Glucarpidase
is. Glucarpidase should be given only in cases if supportive therapy is not effective enough in lowering MTX plasma
levels. Even then, health care professionals should use Glucarpidase cautiously because of its uncertain benefits
unpredictable side effect.
Keywords: Methotrexate; Glucarpidase; Voraxaze; Child;
Intoxication; Toxicity
Introduction
Methotrexate (MTX) is one of the most widely used anticancer
agents. High Dose Methotrexate (HD-MTX) followed by Leucovorin
(LV) rescue is an important component in the treatment of a variety of
childhood and adult cancers. HD-MTX can be safely administered to
patients with normal renal function using of alkalinasation, hydration
and pharmacokinetically guided LV rescue. Despite these measures
HD-MTX-induced renal dysfunction continues to occur in
approximately 1.8% of patients. The mortality among patients who
developed renal dysfunction was 4.4%. In the 1970s, prior to routine
monitoring of plasma MTX concentrations and PK guided adjustment
of LV, the mortality associated with HD-MTX infusions ranged
between 4.6% and 6% [1,2].
MTX-induced renal dysfunction is believed to be mediated by the
precipitation of MTX and its metabolites in the renal tubules or via a
direct toxic effect of MTX on the renal tubules. Without safety
measures following HD-MTX infusion patients present following a
delay of several days with severe mucositis, profound bone marrow
depression and less commonly dermatitis. Rescue attempts with High
Dose Leucovorin had small effect on relieving MTX toxicities. In
addition to conventional treatment approaches, dialysis-based
methods have been used to remove MTX with limited effectivness.
More recently Glucarpidase (Voraxaze®) has become been available
for the treatment of HD-MTX (>1g/m2) induced renal dysfunction [3].
Glucarpidase is a recombinant bacterial enzyme that rapidly
hydrolyzes MTX to inactive metabolites (-95% in 15 minutes). It is not
registered in the EU due to allocation of the production site while
pending at the European Medicine Agency. Glucarpidase1000 IE
powder for injection is priced at € 14431, 64 (vat incl) per vial and
must be ordered per set of two vials. It should be dosed at 50 IE/kg,
dissolved in 1 ml NaCl 0, 9% and injected as an intravenous bolus in 5
minutes. Two hours before and after administration of Glucarpidase
no Leucovorin should be administered due to the fact that Leucovorin
itself is a substrate for Glucarpidase [4].
Before the treatment with Glucapridase is started there should be a
consultation between the physician and the hospital pharmacist where
they can decide, using the most recent MTX blood concentrations and
the patient characteristics (clearance, signs of intoxication such as
mucositis, etc.), if and how the patient should be treated. In the
University Medical Centre Groningen we use a Glucarpidase protocol
in which the initiation of treatment depends on the given MTX dosage,
the MTX infusion duration and measured MTX blood concentrations
(Table 1).
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After the patient treatement with Glucarpidase some questions
raised about:
• The mechanism behind MTX induced nephrotoxicity
• The duration of elevated creatinine levels after treatment with
Glucarpidase and the cause of it
• Resumption of HD-MTX therapy after nephrotoxicity
• Criteria/protocol when and how to use Glucarpidase
MTX dose 1 g/m2 2 g/m2 5 g/m2 4 g/m2 8 g/m2 12
g/m2
Infusion duration 24 hours 4 hours
Hours after start
MTX administration
Limit levels of MTX blood concentrations
(µmol/L)
12 hours ≥ 50 ≥ 100 ≥ 250 ≥ 160 ≥ 310 ≥ 470
24 hours ≥ 50 ≥ 100 ≥ 250 ≥ 25 ≥ 50 ≥ 75
36 hours ≥ 7.5 ≥ 15 ≥ 35 ≥ 5 ≥ 10 ≥ 16
42 hours ≥ 3 ≥ 6 ≥ 16 ≥ 3 ≥ 6 ≥ 9
48 hours ≥ 1.5 ≥ 3 ≥ 7.5 ≥ 2 ≥ 4 ≥ 6
>60 hours ≥ 1 ≥ 1 ≥ 2.5 ≥ 1 ≥ 2 ≥ 3
Tabel 1: Glucarpidase protocol: MTX limit levels at which
Glucarpidase should be given (1 µmol/L=454 µg/L).
Case 1
Patient 1, 17 years old, threated with SKION-EURAMOS 01-M
chemotherapy (10 treatment cycles with a month period between each
cycles) with 24 grams of Methotraxate iv (12 g/m2 in 4 hours, iv), for
osteosarcoma, developed nephrotoxicity with hyperkaliemia after the
tenth treatment cycle.




























LC/MS MTX level was
0.30 µmol/l
122
Day 8 0.8 129 Hyperhydration stop
Day 7 0.7 147
Day 14 0.3 121
Day 25 Not measured 112
Table 2: Laboratory results and therapies applied to the patient.
Before each HD-MTX therapy the attending physicians confirmed
that kindey and liver function were normal, there was no mucositis
present and blood cell counts (leucocytes, granulocytes and
trombocytes) where normal. Urine pH level was at least 7.
2 days after HD-MTX infusion a MTX level in blood sample was
analysed according to the protocol. Measured blood level was 36
µmol/L (ref >1.5 µmol/L) and creatinine level 143 µmol/L. There was
no evident reason for such a high level of MTX. Hyperhydration level
and Leucovorin dose were raised and shortly thereafter resulted in a
decline of MTX blood level (see Table 2). In regards to our own
Glucarpidase protocol and MTX blood levels after 48 hours, use of
Glucarpidase was indicated. Glucarpidase was immediately ordered
through international channels and administered almost 72 hours after
the initial MTX dose. Shortly after the administration of Glucarpidase
there was no sharp decline in MTX level or improvement of kidney
function at a long term. At day 7 there was even a decline in kidney
function. Even 2 weeks after initial treatment with Glucapridase,
creatinine levels did not return to a level before the last HD-MTX
administration. Physicians were not sure how and when they could
restart next MTX chemotherapy.
Case 2
Patient 2, 14 years old, threated according to the SKION ALL 11
HD-MTX chemotherapy (5,000 mg/m2/dose, i.v., over 24 hours, days
8, 22, 36, 50 ) protocol was treated with 10 grams of Methothrexate
(5gr/m2 in 24 hours) for acute limphoblastic leukemia. He developed
nephrotoxicity after the second cycle. There was no evident reason for
such a high level of MTX. Creatinine level before treatment was 64
µmol/l and there were no signs of side-effects caused by the previous
MTX therapy. At day 2 MTX level (67 µmol/l (ref >1.5 µmol/L) and
creatinine level were measured (295 µmol/l) (see Table 3).
It is unknown if supportive therapy/care was given during and after
this period. At day 2 at 22 pm Glucarpidase 1000 IE was given. At day
3 there was a sharp decline in MTX level while creatinine levels stayed
unchanged. At day 4 there was a rebound of MTX because
Glucarpidase doesn`t penetrate the cells in which MTX is stored. The
outflow of MTX from the cells caused an incline in MTX blood levels.
At day 10 there was an acceptable MTX level while for creatinine level
it tooked 19 days to return to a level comparable with day 0. Same as
with case 1, physicians were not sure how and when they could restart
next MTX chemotherapy.
Discussion
The bacterial carboxylasepeptidase-G class of enzymes hydrolyze
the terminal glutamate from MTX. A recombinant form of bacterial
carboxypeptidase, glucarpidase has been developed to treat patients
with HDMTX-induces acute kidney injury. Glucarpidase converts
MTX to, what is believed ``non-toxic`` metabolites such as DAMPA
(4-([2,4-diamino-6-(pteridinyl)methyl]-methylamino-benzoic acid)
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and glutamic acid. It is reported that glucarpidase rapidly reduces
systemic MTX concentration by >95% within 1 hour of administration
and causes little rebound in systemic MTX concentration. Aside















50 312 Glucarpidase 1000 IE
Day 3 0.2 316
Day 4 8.9 293
Day 5 4.4 276
Day 6 2.4 311
Day 7 2 313
Day 8 2.1 278
Day 9 1.7 243








Table 3: Laboratory results and therapies applied to the patient.
One of the unexpected consequences of Glucarpidase therapy in
both patients was a prolonged renal dysfunction. If we compare our
patient data with data we found in the literature there is almost no
difference in duration between patients who got Glucarpidase (median
21 days until full renal recovery) and those with only supportive
therapy (19 and 12 days) [5]. A theoretic concern regarding the use of
Glucarpidase is that the rapid formation of a MTX metabolite called
DAMPA, which is almost 10-fold less soluble than MTX, may lead to
further renal toxicity by precipitation in the renal tubules [5]. One of
the ways to minimize this risk, which should be further investigated, is
probably to administer Glucarpidase in more than 5 minutes together
with hydration. In this way the forming of huge amounts of DAMPA in
short period of time could be prevented. The use of supportive therapy
should always be advised. Our current Glucapridase protocol will be
updated with data on how long it takes for kidney function to fully
recover.
On reviewing the literature we found that almost 19% of the
patients treated with Glucarpidase continued to have grade III-IV
renal toxicity after HD-MTX therapy. In the same article 60% of the
treated patients developed grade III-IV hematological toxicities [2].
There is no data available which compares the occurrence of toxicities
between patients who were treated with Glucarpidase or with
supportive therapy only. If we closely look at our data and available
data from the published literature there is a serious concern about
effectiveness and safety of Glucarpidase.
Our second concern was if the measures taken to prevent the
intoxication were appropriate. Before HDMTX therapy renal and liver
function of both patients were screened en there were no signs of MTX
side effects from previous therapies. Schwartz et al. analyzed the risk
factors contributing to delayed MTX clearance in 43 patients treated
with Glucarpidase [3]. The largest risk factor was a body mass index
>25 kg/m2 followed by relevant comedication (salicylates, NSAID`s,
sulfonamides, beta-lactam antibiotics, aminoglycosides), urine pH<7,
iv fluid intake <3l/m2/24 hours, hepatic dysfunction, renal
insufficiency prior to HD MTX, diarrhea and pleural effusions. None
of the above mentioned risk factors were present in our cases. The
check for relevant comedication is one of the factors that are missing in
our current Glucarpidase protocol.
After treatment with Glucarpidase the question on how and when to
restart HD-MTX therapy arised. Christensen et al. analyzed 13 of 20
patients who received Glucarpidase [2]. These 13 were rechallanged
with HD-MTX within an average period of 28 days after Glucarpidase
therapy. The next HD-MTX therapies (average 39 days) were given
after kidney function fully recovered. 4 of the 13 patients got the full
recommended HD-MTX dose. The rest (9 patients) received a reduced
HD-MTX dose (50-75%). One of the patients who received a reduced
dose developed acute kidney injury and another one developed
neurotoxicity. The conclusion was that the restart of the HD-MTX
therapy after Glucarpidase administration was well tolerated although
close monitoring of both renal function and plasma MTX levels was
necessary. A safe option for our two patients would be first a
rechallenge with 50-75% HD-MTX after full recovery of the renal
function. After first rechallenge kindey function and MTX levels
should be closely monitored and if this goes well the second
rechallenge should be with 100% HD-MTX.
One should also realize that MTX levels analyzed for these patients,
using an immunoassay, not only measure MTX levels but also the
metabolite DAMPA due to cross-reactivity. MTX levels measured by
liquid chromatography mass spectrometry (LC-MS) showed lower
levels of MTX present after the use of Glucarpidase. In patient 1 levels
of MTX (day one and day 2 after Glucarpidase administration) were
three to five times lover when analyzed by LC/MS. An LC/MS method
for analyzing MTX is not present in each hospital due to its complexity
and costs, so analyzing these samples on time acquires adequate
logistics and communication [6,7].
If we look closely at the MTX levels of patient 1 before and after
Glucarpidase therapy we doubt if there is added value of Glucarpidase
in this setting. We see a decline in MTX levels probably caused by the
supportive therapy. After the moment at which Glucarpidase was given
there was no sharp decline in MTX levels compared to patient in case
report 2. Glucarpidase should be given only in cases if supportive
therapy is not effective enough in lowering MTX plasma levels.
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